Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals鈥� 10-K doesn鈥檛 just list numbers; it weaves together antisense pipeline updates, milestone revenues from Biogen and AstraZeneca, and detailed R&D spend that often tops hundreds of millions. Parsing how each clinical program moves from discovery to Phase 3鈥攁nd how those decisions flow through revenue recognition rules鈥攃an be overwhelming.
Stock Titan鈥檚 AI lifts that burden. Our platform delivers Ionis Pharmaceuticals SEC filings explained simply, turning the dense language of a 300-page annual report into plain-English takeaways. Get real-time alerts whenever an Ionis Pharmaceuticals 8-K material events explained filing hits EDGAR, see Ionis Pharmaceuticals insider trading Form 4 transactions the moment executives trade shares, and drill into each Ionis Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side historical comparisons. Need to monitor Ionis Pharmaceuticals executive stock transactions Form 4? Our AI tags every purchase, sale or option exercise and flags unusual patterns.
Whether you鈥檙e projecting future royalty streams, checking how Ionis accounts for partner reimbursements, or reviewing CEO pay in the Ionis Pharmaceuticals proxy statement executive compensation, you鈥檒l find every document鈥�10-K, 10-Q, 8-K, S-8 and more鈥攊ndexed and searchable. Interactive summaries, key metric dashboards, and sentence-level citations let you understand Ionis Pharmaceuticals SEC documents with AI in minutes, not hours. Follow upcoming catalysts with Ionis Pharmaceuticals earnings report filing analysis or set custom alerts for Ionis Pharmaceuticals Form 4 insider transactions real-time; Stock Titan turns regulatory complexity into actionable clarity.
Q2-25 results (ended 30 Jun 25): Ionis generated $452.0 M revenue, +101% YoY, fuelled by a $280 M upfront from Ono (sapablursen), a $30 M milestone from AstraZeneca and $19.3 M of first-time U.S. TRYNGOLZA sales. Royalty streams (mostly SPINRAZA & WAINUA) added $70.0 M.
Operating expenses rose 7% to $312.2 M as SG&A expanded with launches while R&D fell modestly; operating profit reached $139.8 M versus a $66.1 M loss. Net income swung to $123.6 M ($0.70 diluted EPS) from a $66.3 M loss.
H1-25: Revenue climbed 69% to $583.7 M; net loss narrowed to $23.4 M. Operating cash flow was essentially breakeven ( $0.6 M) versus a $269.8 M outflow a year earlier.
Balance sheet: Cash increased to $297.3 M; cash + short-term investments totalled ~$2.29 B. Shareholders鈥� equity improved to $631.7 M. Current liabilities grew to $897.2 M after the 0% convertible notes ($630.1 M) moved current; total liabilities stand at $2.35 B.
Strategic updates: 1) Ono deal brings up to $940 M future milestones; 2) AstraZeneca advanced opemalirsen into Phase 2b; 3) first independent commercial launch with FDA-approved TRYNGOLZA for FCS. Company maintains single-segment reporting and full valuation allowance on deferred tax assets.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
